CAS No.
[570406-98-3 (Unlabelled)]
Storage Condition
Refer MSDS for complete information
Synonyms
1-(3-chloro-5-((4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl-2,2,3,3,5,5,6,6-d8)thiazol-2-yl)carbamoyl)pyridin-2-yl)piperidine-4-carboxylic acid
Application Notes
Useful research chemical for a range of applications
Hazard Compound
Refer MSDS for complete information
Avatrombopag-d8 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Avatrombopag-d8 usage and description
Avatrombopag d8 is a deuterated version of Avatrombopag, a small molecule agonist of the thrombopoietin receptor used for the treatment of thrombocytopenia in patients with chronic liver disease. Thrombocytopenia is a condition characterized by a low platelet count in the blood, which can lead to excessive bleeding or bruising. Avatrombopag d8 works by stimulating the production of platelets in the bone marrow, thereby increasing the platelet count in the blood.
Chemically, Avatrombopag d8 is a deuterated derivative of Avatrombopag, which means that some of the hydrogen atoms in the molecule have been replaced with deuterium atoms. This modification results in a heavier molecule, which has several advantages over the non-deuterated version. For example, Avatrombopag d8 has a longer half-life in the body, which means that it can be administered less frequently. Additionally, deuterated molecules are often more stable than their non-deuterated counterparts, which can reduce the risk of side effects and improve the efficacy of the drug.
Avatrombopag d8 is typically administered orally, in the form of a tablet. The recommended dose varies depending on the patient's weight and medical history, and should be determined by a qualified healthcare professional. Common side effects of Avatrombopag d8 include headache, nausea, and fatigue. In rare cases, the drug may cause more serious adverse reactions, such as liver toxicity or blood clots. Patients taking Avatrombopag d8 should be closely monitored by a healthcare professional to ensure that the drug is safe and effective for their specific condition.
